Fas配体在髓系白血病细胞中的表达及功能研究

为了解Fas配体 (FasL)在髓系白血病细胞中的表达水平及其诱导Fas+敏感细胞发生凋亡的功能 ,用流式细胞术检测 38例髓系白血病患者 (外周血白细胞 >10 0× 10 9/L)的白血病细胞在新鲜分离及IL 2和IFN γ刺激后表面膜FasL的表达水平 ,将白血病细胞 ( 1× 10 6/ml)与Jurkat细胞 ( 1× 10 5/ml)混合培养 2 4小时后 ,用DNA电泳和流式细胞术双标法检测Jurkat细胞发生凋亡的情况。结果表明 :白血病细胞表面FasL表达量 ( 3.5 9± 1.0 5 ) %高于正常人 ( 0 .36± 0 .16 ) % ,P <0 .0 0 1,经IL 2和IFN γ刺激后其表达量明显增加 ( 7.78± 3.4 0 ) % ,P <0 .0 1;白血病细胞刺激前后诱导Jurkat细胞发生的凋亡率分别为 ( 8.2 8± 1.6 1) % ,( 10 .73± 2 .16 ) % ,差异具有显著性意义。结论 :FasL在髓系白血病细胞表面高表达且对Fas+的敏感细胞具有杀伤功能 ,推测Fas/FasL途径可能在白血病的“免疫逃逸”中发挥作用

Study on Expression and Function of Fas Ligand in Human Myeloid Leukemia Cells

To determine whether the Fas receptor-Fas ligand (FasR-FasL) system, which triggers apoptosis in sensitive cells, is an important mechanism of cytotoxicity in myeloid leukemia. FasL expression was investigated in myeloid leukemia cells and its upregulation by a combination of IL-2 and INF-gamma, +/- as well as its function of inducing Jurkat cells to apoptosis mainly by flow cytometry (FCM). Results showed that leukemia cells expressed more FasL (3.59 +/- 1.05)% than that expressed in the healthy individuals (0.36% +/- 0.16)%, P < 0.001 and the FasL was upregulated (7.78 +/- 3.40)%, P < 0.01 when treated with IL-2 and IFN-gamma. Leukemia cells were co-cultivated with Jurkat cells for 24 hours. Then Jurkat cells were labeled with FITC-annexin V and PE-CD3 to assess apoptosis by FCM. The leukemia cells, which had been incubated with IL-2 and IFN-gamma, induced more Jurkat cells to apoptosis than the ones that freshly isolated from the peripheral blood mononuclear cells, which raised the figure from (8.28 +/- 1.61)% to (10.73 +/- 2.16%). And the supernatant derived from the former killed more Jurkat cells than the latter. It was concluded that human myeloid leukemia cells expressed high levels of functional FasL that can kill Jurkat T-cells by apoptosis. FasR-FasL sys tem could play a role in the "immune escape" and relapse of the leukemia. The induction of apoptosis through the Fas pathway might be a novel and effective approach for leukemia immunotherapy.